King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
22:53
Tourist from France, injured on the Semenic-Gărâna route
22:41
Dan Jørgensen says that the European electricity market withstands pressure, but calls for more storage and flexibility
22:39
On Tuesday evening, Romania consumed over 8,000 MW of electricity, with a production of 5,873 MW
22:23
The Russian Ministry of Foreign Affairs has asked Armenia to decide by December between the European Union and the Eurasian Economic Union.
22:11
Apple will launch an anniversary model of the iPhone made of glass / Analysts at Jefferies have downgraded the stock rating due to rumors about its cancellation.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
